CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.(CELZ)Stock Analysis

AI analysis on 2,800+ stocks →
HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1187953CELZ stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

CELZ Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ), a Healthcare sector company. CELZ is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Top institutional holders of CELZ by reported 13-F value include Hudson Bay Capital Management, Anson Funds Management, ARMISTICE CAPITAL, based on the most recent SEC filings. CELZ trades on the Nasdaq exchange and files with the SEC under CIK 1187953. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. directly from SEC EDGAR.

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-1.5M

ROIC

Q2 2026

-72.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-45.5% YoY
$6.0KFY 2025
FY22 $88.6KFY23 $9.0KFY24 $11.0KFY25 $6.0K

Net Income

-9.1% YoY
$-6.0MFY 2025
FY22 $-10.1MFY23 $-5.3MFY24 $-5.5MFY25 $-6.0M

Operating Income

-6.9% YoY
$-6.1MFY 2025
FY22 $-10.2MFY23 $-5.6MFY24 $-5.7MFY25 $-6.1M

EPS (Diluted)

+32.1% YoY
$-2.52FY 2025
FY22 $-0.93FY23 $-3.76FY24 $-3.71FY25 $-2.52

Total Assets

+17.1% YoY
$7.8MFY 2025
FY22 $19.2MFY23 $10.7MFY24 $6.7MFY25 $7.8M

Op. Cash Flow

-10.5% YoY
$-5.9MFY 2025
FY22 $-7.8MFY23 $-8.0MFY24 $-5.3MFY25 $-5.9M

Get alerted when CELZ's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put CELZ on your watchlist

Track score changes the day CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is CELZ a good stock to buy?

13F Pro's AI-powered analysis of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CELZ are available on the CELZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CELZ is classified as a small company.

Which hedge funds own CELZ?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CELZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s investment landscape.